SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-160348
Filing Date
2023-06-05
Accepted
2023-06-05 08:20:53
Documents
13
Period of Report
2023-06-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d513071d8k.htm   iXBRL 8-K 25739
2 EX-99.1 d513071dex991.htm EX-99.1 15307
  Complete submission text file 0001193125-23-160348.txt   172563

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20230605.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20230605_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20230605_pre.xml EX-101.PRE 11702
7 EXTRACTED XBRL INSTANCE DOCUMENT d513071d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 23991297
SIC: 2836 Biological Products, (No Diagnostic Substances)